Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +57.64% | +52.35% | +46.34% | +14.68% | +122.85% |
| Gross Profit Growth | +33.81% | +51.21% | +103.34% | -21.35% | +130.54% |
| EBITDA Growth | +0.00% | -213.54% | -133.14% | +0.00% | +4294.35% |
| Operating Income Growth | +2.11% | +0.00% | -1312.05% | +0.00% | +1647.73% |
| Net Income Growth | +0.00% | -270.93% | -149.28% | +0.00% | +0.00% |
| EPS Growth | +0.00% | -257.69% | -145.47% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | -259.22% | -146.53% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +5.98% | +8.63% | +8.23% | +7.21% | +5.15% |
| Weighted Average Shares Diluted Growth | +5.98% | +7.34% | +5.90% | +10.53% | +9.51% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +377.77% | +300.10% | -236.51% | +18.65% | -63.97% |
| Free Cash Flow Growth | +211.34% | +314.38% | -238.44% | +39.45% | -41.02% |
| Receivables Growth | +17.02% | +7.98% | +50.63% | +12.37% | +37.89% |
| Inventory Growth | -47.07% | -41.12% | -44.63% | -10.94% | -11.46% |
| Asset Growth | +24.13% | +19.63% | -0.92% | +9.49% | +54.66% |
| Book Value per Share Growth | +18.84% | +9.06% | -8.86% | -0.30% | +7.43% |
| Debt Growth | +16.24% | +15.25% | -28.19% | -24.28% | +6030.18% |
| R&D Expense Growth | +2.58% | -19.37% | +738.80% | +22.66% | +270.38% |
| SG&A Expenses Growth | +67.00% | +60.11% | +71.68% | +14.48% | +16.22% |